Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 2346 • ACR Convergence 2025
Back in Action: Six Months of Biological Therapy Improve Sexual Function in Men with Ankylosing Spondylitis
Daniel Zavada¹, Barbora Vala², Adela Navratilova², Veronika Losterova², Lenka Moravcova², Jiri Vencovsky³, Ladislav Šenolt⁴, Karel Pavelka⁵ and Michal Tomcik⁵, ¹Institute of Rheumatology, Prague; Charles University, Third Faculty of Medicine, Hlavné mesto Praha, Czech Republic, ²Institute of Rheumatology, Praha, Czech Republic, ³Institute of Rheumatology, Praha ⁸, Czech Republic, ⁴Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, ⁵Institute of Rheumatology and Department of Rheumatology, ¹st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic
Background/Purpose: Ankylosing spondylitis (AS) significantly impacts quality of life across multiple domains. To date, no studies have evaluated the impact of initial biological therapy on…
Abstract Number: 1979 • ACR Convergence 2025
Utility of ALT/AST and Fibrosis-4 Index (FIB-4) Score in Monitoring Methotrexate Hepatotoxicity in Rheumatologic Disease: A Retrospective Analysis
Julia Wajsberg¹, Dana Nachawati², Lenche Kostadinova³, Donald Anthony⁴ and Maya Mattar³, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University Hospitals, Cleveland, ³Louis Stolkes Cleveland VA, Cleveland, ⁴The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Methotrexate (MTX) is widely used in rheumatologic disease but carries hepatotoxic risk. Standard monitoring relies on measurement of alanine and aspartate aminotransferase (ALT and…
Abstract Number: 1438 • ACR Convergence 2025
Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
Félicie Costantino¹, Ann-Sophie De Craemer², Filip Van den Bosch², Maxime Breban³, Vanessa Taieb⁴, Diana Voiniciuc⁵, Natasha de Peyrecave⁶, Dirk Elewaut⁷ and Maria-Antonietta D'Agostino⁸, ¹Department of Rheumatology, Ambroise Paré Hospital, AP-HP, Paris, France and Infection & Inflammation, UMR ¹¹⁷³, Inserm, UVSQ/Université Paris Saclay, Montigny-Le-Bretonneux, France, ²Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ³CHU Ambroise-Paré, Boulogne-Billancourt, France, ⁴UCB, Colombes, France, ⁵UCB, Slough, United Kingdom, ⁶UCB, Brussels, Belgium, ⁷VIB Center for Inflammation Research, and Ghent University Hospital, Department of Rheumatology, Ghent, Belgium, ⁸Department of Rheumatology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease mainly affecting the sacroiliac joints and spine.1 Peripheral manifestations are common, contributing to disease burden.2 Two…
Abstract Number: 1118 • ACR Convergence 2025
Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
Settawut Buadee¹, Kittikorn Wilasrusmee¹, Tanakrit Kamonsumlitpon¹, Sirirat Charuvanij², Ekapun Karoopongse³ and Praveena Chiowchanwisawakit⁴, ¹Medical Student, Faculty of Medicine, Siriraj Hospital, Mahdol University, Bangkok, Thailand, ²Division of Rheumatology, Department of Pediatrics, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ³Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ⁴Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
Background/Purpose: To estimate the incidence and identify associated factors of azathioprine (AZA)-induced leukopenia.Methods: A retrospective cohort study was conducted on 1,062 adult patients with non-malignant…
Abstract Number: 0579 • ACR Convergence 2025
Characteristics and Treatment Patterns among Patients with Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry Initiating a Third or Higher Line of Biologic or Targeted Disease-Modifying Antirheumatic Drug Therapy
Philip J. Mease¹, Nicole Middaugh², Yolanda Muñoz Maldonado², Chao Song³, Melissa Eliot², Robert Low³ and Alexis Ogdie⁴, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³UCB, Smyrna, GA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease affecting the joints, skin, and other regions of the body. It impacts up to 36%…
Abstract Number: 0500 • ACR Convergence 2025
Is Methotrexate Tapering Possible In Stable RA? Clinical Observations of Methotrexate Tapering At Two Tertiary Care Centers
Sama Hajizadeh¹, Tarun Sharma¹, Peri Newman², Julio Hernandez², Rayford June³, Erik Lehman², Nicole Wilson¹, Nancy Olsen⁴ and Sharon Banks⁵, ¹Allegheny Health Network, Pittsburgh, PA, ²Penn State Health/ Penn State College of Medicine, Hershey, PA, ³Penn State College of Medicine/Lebanon VA Medical Center, Hummelstown, PA, ⁴Penn State University/Milton S Hershey, Hershey, PA, ⁵Penn State Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: In our previous Rheumatoid Arthritis Medication TAPering (RheumTAP) cohort study of patients with stable RA in remission on biologics +/- methotrexate at Allegheny Health…
Abstract Number: 0392 • ACR Convergence 2025
Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)
Abigale Jagger¹, Mara Becker², Susan Thompson³, Mekibib Altaye⁴, John Bohnsack⁵, Hermine Brunner⁶, Margaret Chang⁷, Ashley Cooper⁸, Stefanie Davidson⁹, Alexandra Duell⁶, Bharti Gangwani⁷, Carl Langefeld¹⁰, Melissa Lerman¹¹, Mindy Lo⁷, Serena Pastore¹², Mariia Pavlenko¹³, Sampath Prahalad¹⁴, Megan Quinlan-Waters¹⁵, Laura Ramsey¹⁶, Grant Schulert⁶, Gabriele Simonini¹⁷, Erin Stahl⁸, Gabriele Stocco¹⁸, Marc Sudman¹⁹, Andrea Taddio¹⁸, Virginia Miraldi Utz⁶, Rae Yeung²⁰ and Sheila Angeles-Han¹, ¹Cincinnati Children's Hospital, Cincinnati, OH, ²Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ³Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, ⁴Cincinnati Children's Hospital, Cincinnati, ⁵University of Utah, Salt Lake City, UT, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Boston Children's Hospital, Boston, MA, ⁸Children's Mercy Kansas City, Kansas City, MO, ⁹University of Pennsylvania/CHOP, Philadelphia, PA, ¹⁰Wake Forest University School of Medicine, Winston Salem, NC, ¹¹Children's Hospital of Philadelphia, Philadelphia, PA, ¹²Institute of Child and Maternal Health - IRCCS "Burlo Garofolo", Trieste, Italy, ¹³Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, ¹⁴Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁵Cincinnati Children's Hospital Medical Center, CCHMC, ¹⁶Children's Mercy, Kansas City, MO, ¹⁷Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, ¹⁸Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ¹⁹Cincinnati Children's Hospital Medical Center, Cincinnati, ²⁰The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…
Abstract Number: 2307 • ACR Convergence 2025
Peripheral Manifestations In Axial And Peripheral Spondyloarthritis: A Systematic Literature Review On Their Assessment In Clinical Trials
AUGUSTA ORTOLAN¹, Casper Webers², Elena Nikiphorou³, Alexandre Sepriano⁴, Louise Falzon⁵, Clementina López Medina⁶, Dafne capelusnik⁷, Désirée Van Der Heijde⁸, Anna Molto⁹ and Sofia Ramiro¹⁰, ¹Policlinico Universitario Agostino Gemelli IRCSS, Rome, Italy, ²Maastricht University Medical Centre, Maastricht, Netherlands, ³King's College London, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Centre, Portela Loures, Portugal, ⁵Sheffield Centre for Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain, ⁷Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁸Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁹Assistance Publique Hôpitauxde Paris, Paris, France, ¹⁰Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Peripheral manifestations (peripheral arthritis, enthesitis, dactylitis) of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) represent a significant burden for patients, but are understudied. Our…
Abstract Number: 1831 • ACR Convergence 2025
Distinct Proteomic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Christian Wright¹, Miles Smith², Rufei Lu², Catriona Wagner³, Aleksandra Bylinska², Carla Guthridge², Nicholas Domingez², Susan Macwana², Wade DeJager⁴, Marci Beel⁵, Joan Merrill⁶, Eliza Chakravarty², Ellen Goldmuntz⁷, Study Team ALE⁰⁶ Clinical⁸, Judith James² and Joel Guthridge², ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma city, OK, ³Oklahoma Medical Research Foundation, Santa Cruz, CA, ⁴Oklahoma Medical Research Foundation, Oklahoma City, ⁵Oklahoma Medical Research Foun, Oklahoma City, OK, ⁶Oklahoma Medical Research Foundation, Oklahoma City ⁷³¹⁰⁴, OK, ⁷NIAID/ NIH, Washington, DC, ⁸Autoimmunity Center of Excellence, Oklahoma City, OK
Background/Purpose: : Systemic Lupus Erythematosus (SLE) follows a characteristic relapsing-remitting course with unpredictable flares interspersed with periods of relative quiescence. Mycophenolate mofetil (MMF) has emerged…
Abstract Number: 1364 • ACR Convergence 2025
Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
Prativa Priyadarshani Sethi¹, Venkatesh Srinivasa Pai², Rajat Ranka², Avneet Kumar Gupta³, Ashish Baweja⁴, ritu sangwan⁵, Abhishek Rai⁶, Sryla Punjadath¹ and Nithya Maskani², ¹All India Institute of Medical Sciences, Rishikesh, Rishikesh, Uttarakhand, India, ²AIIMS RISHIKESH, Rishikesh, Uttarakhand, India, ³AIIMS RISHIKESH, Lucknow, Uttar Pradesh, India, ⁴Medanta, The Medicity, Gurugram, New Delhi, Delhi, India, ⁵AIIMS ,Rishikesh, Rishikesh, Uttarakhand, India, ⁶AIIMS ,RISHIKESH, Bhilai, Chhattisgarh, India
Background/Purpose: Early rheumatoid arthritis (RA) is a critical therapeutic window where prompt treatment targeting remission or low disease activity can significantly reduce long-term disability and…
Abstract Number: 1114 • ACR Convergence 2025
Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Mei-Feng Shi¹, Fang-Shu Zou¹, Xiao-Na Ma¹, Wei Feng¹, Yi-Fang Zhang², Chang-Song Lin¹, Min-Ying Liu² and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²The First Clinical Medical College of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic)
Background/Purpose: Methotrexate (MTX) is a first-line treatment for autoimmune diseases, including rheumatoid arthritis (RA). Its potential risk of inducing type 2 diabetes mellitus (T2DM) remains…
Abstract Number: 0572 • ACR Convergence 2025
Real-World Treat-to-Target Strategy in Psoriatic Arthritis: 48-week Results from the MONITOR-PsA Cohort
Jean-Guillaume Letarouilly¹, Elnaz Saeedi², Raphaël Hurtubise³, Lija James⁴, Nicola Gullick⁵, Deepak Jadon⁶, William Tillett⁷, Yvonne Sinomati⁴, Laura Tucker⁴, Nadia Mian⁸, Sophia Massa³ and Laura Coates⁹, ¹Université de Lille, CHU Lille, Service de rhumatologie, Lille, France, LILLE, Nord-Pas-de-Calais, France, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK., Oxford, United Kingdom, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ⁵Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁶Department of Medicine, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ⁷Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ⁸BM BS, MMedSc,, Oxford, United Kingdom, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom
Background/Purpose: A treat-to-target (T2T) strategy in psoriatic arthritis (PsA) is supported by International PsA recommendations but not widely practiced in clinic. The aim of the…
Abstract Number: 0497 • ACR Convergence 2025
Drug Survival and Discontinuation Reasons of Eight Biological Disease-Modifying Antirheumatic Drugs in 1,182 Patients with Rheumatoid Arthritis: A Retrospective Study Using the Niigata Orthopedic Rheumatoid Arthritis Database (NOSRAD)
Nariaki Hao and Naoki Kondo, Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital, Niigata, Japan
Background/Purpose: To retrospectively evaluate drug survival and reasons for discontinuation of eight biological disease-modifying antirheumatic drugs (bDMARDs) in rheumatoid arthritis (RA) patients using the Niigata…
Abstract Number: 0369 • ACR Convergence 2025
Real-World Persistence of Janus Kinase Inhibitors in Biologic-Experienced Patients with Rheumatoid Arthritis
Jeffrey Curtis¹, Emily Holladay², Nick McCormick³, Yujie Su⁴, Fenglong Xie¹ and Alexis Dineen⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Edmond, OK, ³Auburn University, Auburn, AL, ⁴University of Alabama at Birimingham, Birmingham, AL, ⁵Self, Portola Valley, CA
Background/Purpose: Over the last decade, Janus kinase inhibitors (JAKs) for RA have been increasingly used as a treatment option for patients who do not respond…
Abstract Number: 2290 • ACR Convergence 2025
Patterns and Predictors of Clinical Improvement in Patients with Sjögren’s Disease: A Longitudinal Analysis of ESSDAI and ESSPRI Improvements
Alejandro Gómez Gómez¹, Sergio H. Martínez Mateu², Jose Luis Tandaipan³, Monica Fernandez Castro⁴, Guillermo gonzalez⁵, Sheila Melchor-Díaz⁶, Miren Uriarte Ecenarro⁷, Raúl Menor Almagro⁸, Paloma Vela Casasempere⁹, Beatriz Paredes-Romero¹⁰, Judit Font-Urgelles¹¹, Paula Estrada-Alarcón¹², Sara Manrique-Arija¹³, Mª Angeles Blazquez Cañamero¹⁴, Clara Moriano¹⁵, Juan José Alegre-Sancho¹⁶, Marina Rodríguez López¹⁷, Marta López¹⁸, Gema Bonilla¹⁹, Rafaela Ortega-Castro²⁰, Sara Maria Rojas Herrera²¹, Ignacio Braña²², Lilian López-Núñez²³, Javier Narváez²⁴, Jose Rosas Gómez de Salazar²⁵, Ruben D. López-Sánchez²⁶, Carles Galisteo Veiga²⁷, Javier Martínez-Ferrin²⁸, Jose Javier Pérez Venegas²⁹, Guadalupe Manzano-Canabal³⁰, Cilia Peralta-Ginés³¹, Lara Sánchez Bilbao³², José Andrés Román Ivorra³³, Rafael Cáliz-Cáliz³⁴, Belén Serrano-Benavente³⁵, Sabela Fernández-Aguado³⁶, Natalia Boix- Martí³⁷, Eric Kirkegaard-Biosca³⁸, Iago Alvarez Saez³⁹, Ares Selles-Rius⁴⁰, Maribel Pérez⁴¹, Juan Cañete⁴², Sara Marsal¹ and Jose Luis Andreu⁴³, ¹Vall d'Hebron Hospital Research Institute, Rheumatology Research Group, Barcelona, Spain, ²IMIDomics, Barcelona, Spain, ³Rheumatology. Hospital Universitario de la Santa Creu i Sant Pau, Barcelona, Spain, ⁴PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁵Hospital Universitario de A Coruña, A Coruña, Spain, ⁶Hospital Universitario ¹² de Octubre, Rheumatology, Madrid, Madrid, ⁷Hospital Universitario La Princesa, Madrid, Spain, ⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁹Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁰Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ¹¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹²Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ¹³Hospital Regional Universitario Málaga, Malaga, Spain, ¹⁴Hospital Ramon y Cajal, Madrid, Spain, ¹⁵Hospital León, LEON, Castilla y Leon, Spain, ¹⁶Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁷Complejo Hospitalario Universitario de Santiago, Rheumatology, Santiago de Compostela., Santiago de Compostela, Spain, ¹⁸Complex Hospitalari Universitari Moisés Broggi, Barcelona, Spain, ¹⁹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ²⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ²¹Hospital de Mérida, Rheumatology, Badajoz, Badajoz, Spain, ²²Hospital Universitario Central de Asturias, Oviedo, Spain, ²³Hospital Son Llatzer, Rheumatology, Palma de Mallorca, Palma de Mallorca, Spain, ²⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ²⁵Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ²⁶Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ²⁷Hospital Parc Taulí, Rheumatology, Sabadell, Sabadell, Spain, ²⁸Hospital Universitario Virgen de la Arrixaca, Rheumatology, Murcia, Murcia, Spain, ²⁹Virgen Macarena University Hospital, Sevilla, Spain, Sevilla, Spain, ³⁰Hospital Virgen de la Concha (Zamora), Zamora, Spain, ³¹Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ³²Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, ³³Hospital Universitari i Politècnic La Fe, Valencia, Spain, ³⁴Hospital Universitario Virgen de las Nieves, Rheumatology, Granada, Granada, Spain, ³⁵Hospital Gregorio Marañon, Madrid, Spain, ³⁶Hospital Universitario de Pontevedra, Pontevedra, Spain, ³⁷Hospital Univetsitari Vall d'Hebron, Rheumatology Department, Barcelona, Spain, ³⁸Hospital Univetsitari Vall d'Hebron, Ophthalmology Department, Barcelona, Spain, ³⁹Hospital Univetsitari Vall d'Hebron, Maxilofacial Surgery Department, Barcelona, Spain, ⁴⁰Rheumatology Research Group, Vall d'Hebron University Hospital, Barcelona, Spain, ⁴¹IMIDomics, Barcelona, Barcelona, Spain, ⁴²Rheumatology Department, Hospital Clínic and IDIBAPS, Barcelona, Spain, Barcelona, Spain, ⁴³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Assessing clinical improvements in Sjögren's Disease (SjD) is challenging. Our objective was to describe patterns of improvement in SjD using ESSDAI and ESSPRI indices…

1
2
3
…
48
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].